Company Description
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease.
It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
| Country | United States |
| Founded | 2003 |
| IPO Date | Apr 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 264 |
| CEO | Kenneth Galbraith |
Contact Details
Address: 108 Patriot Drive, Suite A Middletown, Delaware 19709 United States | |
| Phone | 302 274 8744 |
| Website | zymeworks.com |
Stock Details
| Ticker Symbol | ZYME |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001403752 |
| CUSIP Number | 98985W102 |
| ISIN Number | US98985Y1082 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Scott Platshon | Acting Chief Investment Officer |
| Dr. Paul A. Moore Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 24, 2022 | 15-12G | Securities registration termination |
| Oct 21, 2022 | 8-K | Current Report |
| Oct 19, 2022 | 8-K | Current Report |
| Oct 18, 2022 | 8-K | Current Report |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |